Ulcerative Colitis Mayo Score With Artificial Intelligence
Launched by THIRD MILITARY MEDICAL UNIVERSITY · Apr 14, 2022
Trial Information
Current as of May 29, 2025
Unknown status
Keywords
ClinConnect Summary
In this project, artificial intelligence was used to colonoscopic images of patients with ulcerative colitis with different disease activity levels and classify them according to the evaluation standard Mayo score to assist endoscopists in identifying disease activity levels of patients with ulcerative colitis during colonoscopy. It can help clinical endoscopists to accurately identify, and the visualization technology of artificial intelligence category response map can comprehensively display the areas with high importance for deep network classification results, and visualize the experim...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Subjects were 18-72 years old, male and female;
- • 2. Clinical diagnosis of ulcerative colitis;
- • 3. The subjects underwent colonoscopy and the colonoscopy report was complete.
- Exclusion Criteria:
- • 1. Subjects are younger than 18 years old or older than 72 years old;
- • 2. Subjects underwent colectomy, ileostomy, colostomy, ileostomy, or other intestinal resection;
- • 3. subjects with ambiguous diagnosis.
About Third Military Medical University
Third Military Medical University is a leading medical research institution located in China, renowned for its commitment to advancing healthcare through innovative clinical research and education. With a strong emphasis on military and civilian health, the university integrates cutting-edge scientific methodologies and interdisciplinary collaboration to enhance patient outcomes. Its robust clinical trial framework supports a diverse range of studies, fostering the development of new therapeutic interventions and contributing to the global body of medical knowledge. Through rigorous ethical standards and a focus on translational research, Third Military Medical University aims to address critical health challenges and improve community health on both local and international levels.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chongqing, Chongqing, China
Patients applied
Trial Officials
Yanling Wei, Professor
Study Director
Third Military Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials